Does Rallies show Form 4 insider transactions for BVS?

Yes. Rallies tracks BVS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is BVS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BVS. It does not provide personalized investment advice.

BVS (Bioventus Inc. Class A Common Stock) Stock Analysis - Insider Trades

Bioventus Inc. Class A Common Stock (BVS) is a publicly traded Healthcare sector company. As of May 21, 2026, BVS trades at $10.92 with a market cap of $720.16M and a P/E ratio of 25.49. BVS moved +2.44% today. Year to date, BVS is +44.52%; over the trailing twelve months it is +56.51%. Its 52-week range spans $5.81 to $14.38. Analyst consensus is strong buy with an average price target of $14.33. Rallies surfaces BVS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading BVS stock inside the company?

Recent BVS insider activity includes McMurry-Heath Michelle sold 12.00K, NOHRA GUY P sold 10.00K, McMurry-Heath Michelle sold 17.70K, Singleton Mark Leonard sold 3.88K, and D'Adamio Anthony sold 2.96K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

BVS Key Metrics

Key financial metrics for BVS
Metric	Value
Price	$10.92
Market Cap	$720.16M
P/E Ratio	25.49
EPS	$0.43
Dividend Yield	0.61%
52-Week High	$14.38
52-Week Low	$5.81
Volume	10
Avg Volume	0
Revenue (TTM)	$576.30M
Net Income	$34.54M
Gross Margin	68.69%

Recent BVS Insider Trades

McMurry-Heath Michelle sold 12.00K (~$105.44K) on Mar 11, 2026.
NOHRA GUY P sold 10.00K (~$75.66K) on Dec 4, 2025.
McMurry-Heath Michelle sold 17.70K (~$131.25K) on Nov 7, 2025.
Singleton Mark Leonard sold 3.88K (~$29.33K) on Apr 11, 2025.
D'Adamio Anthony sold 2.96K (~$22.39K) on Apr 11, 2025.

Latest BVS News

Bioventus Q1 Revenue Rises 7% to $132.1M with $3.1M Profit — May 6, 2026
Bioventus Q4 Organic Growth 10%, EBITDA Up 30% to $37M and $38M Cash Flow — Mar 6, 2026
Bioventus Posts 500-Basis-Point EBITDA Margin Expansion, Q4 Cash Hits $38 Million — Mar 5, 2026
Bioventus Delivers $14.8M Q4 Profit, Guides 2026 EPS To $0.73–$0.77 — Mar 5, 2026

BVS Analyst Consensus

4 analysts cover BVS: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $14.33.

Common questions about BVS

Who is trading BVS stock inside the company?: Recent BVS insider activity includes McMurry-Heath Michelle sold 12.00K, NOHRA GUY P sold 10.00K, McMurry-Heath Michelle sold 17.70K, Singleton Mark Leonard sold 3.88K, and D'Adamio Anthony sold 2.96K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for BVS?: Yes. Rallies tracks BVS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is BVS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BVS. It does not provide personalized investment advice.